The people enrolled were no longer the correct population for the study... there are additional studies going on with other populations....BD
WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced the discontinuation of ACHIEVE (An Assessment of Coronary Health Using an Intima-Media Thickness Endpoint for Vascular Effects), an imaging study evaluating MK-0524A (ER niacin/laropiprant) in patients with Heterozygous Familial Hypercholesterolemia (HeFH).
The study was discontinued at the recommendation of the Steering Committee based on its review and evaluation of scientific data from recent carotid intima-media thickness (cIMT) studies. This decision follows the March 29 Steering Committee recommendation to put patient enrollment on hold. The action to discontinue the study is not related to the recent Not Approvable FDA letter on MK-0524A, and preliminary data did not suggest any safety concerns.